Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 28:12:369-376.
doi: 10.2147/JBM.S271478. eCollection 2021.

Trends of Ordering Hypercoagulability Work-Up at an Academic Medical Center

Affiliations

Trends of Ordering Hypercoagulability Work-Up at an Academic Medical Center

Marjan Alidoost et al. J Blood Med. .

Abstract

Background: Venous thromboembolism is a significant clinical event, with an annual incidence of 1-2 per 1000 population. Risk factors include recent surgery, prolonged immobility, oral contraceptive use, and active cancer. Inherited risks include protein C and S deficiencies, antithrombin deficiency, factor V Leiden mutation and prothrombin. These factors can be tested to guide therapy, but current evidence suggests that testing for inherited thrombophilia is not recommended in most inpatient settings. In the era of high value care, hypercoagulable testing for VTE creates a financial burden for the hospital and patients. We performed a retrospective chart review of hypercoagulable orders on VTE patients at our institution.

Methods: Institutional Review Board approval was obtained. A total of 287 adult patients admitted over a 3-month period with the diagnosis of VTE were included. Patients were identified via ICD-10 codes and data were collected from electronic medical records. Patient characteristics, provoked versus unprovoked VTE, and relative contraindications for hypercoagulability work-up were analyzed. Our primary outcome was to assess the appropriateness of thrombophilia testing in VTE patients based on screening guidelines. Our secondary outcome was to analyze the cost burden of ordering these tests.

Results: A total of 287 patients were included in our data analysis. Patient risk factors for VTE were malignancy, previous DVT, immobilization, surgery 3 months prior, and central line placement. Fifty-seven of 287 patients had at least one hypercoagulable test ordered during hospitalization which did not adhere to guidelines. Misuse of testing occurred during active thrombosis, active anticoagulation, presence of risk factors, first episode of VTE, and malignancy. The cost of ordering these 5 thrombophilia tests totaled over $40,000.

Conclusion: In our study, numerous patients were tested without compliance to standard recommendations, which created financial and value-based burdens on our health care system. Increased awareness among clinicians is thus warranted to ensure high value care.

Keywords: VTE; hypercoagulability; thrombophilia; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Dr Michael J Levitt is a member of the Speakers' Bureau for Amgen, Takeda, and GlaxoSmithKline, outside the submitted work. The authors declare that there is no other conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Suggested algorithm for determining the need for a hypercoagulability work-up.
Figure 2
Figure 2
Analysis of why the hypercoagulability work-up was ordered unnecessarily.
Figure 3
Figure 3
Analysis of relative indications present in patients who received thrombophilia work-up.

Similar articles

References

    1. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699. doi:10.1111/j.1538-7836.2007.02450.x PMID: 17367492. - DOI - PubMed
    1. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel Report [published correction appears in Chest. 2016 Oct;150(4):988]. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026 - DOI - PubMed
    1. Pollak AW, McBane RD. Succinct review of the new VTE prevention and management guidelines. Mayo Clin Proc. 2014;89(3):394–408. doi:10.1016/j.mayocp.2013.11.015 - DOI - PubMed
    1. Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology Am Soc Hematol Educ Program. 2016;2016(1):1–9. doi:10.1182/asheducation-2016.1.1 - DOI - PMC - PubMed
    1. Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Hematology Am Soc Hematol Educ Program. 2013;2013(1):9–14. doi:10.1182/asheducation-2013.1.9 - DOI - PubMed

LinkOut - more resources